drugset
drugset / Trial / NCT05707390

A Study of Mezigdomide in Healthy Participants and Participants With Hepatic Impairment

NCT05707390 ↗

Phase 1 Completed 32 enrolled Bristol-Myers Squibb
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The aim of this study is to measure the concentration levels of mezigdomide in the blood of participants with mild, moderate, and severe hepatic impairment, and in matched healthy control participants with normal hepatic function.

Timeline

Start
2023-02-20
Primary completion
2023-09-13
Completion
2023-09-13

Drugs

EvaluationDrugModalityDoseRoute
Subject Mezigdomide Small molecule — —

Indications

No indication recorded.